Team 1
0
Team 2
0
Teams
Name
Score
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
Loading
15
×
Which DOAC is contraindication if CrCl >95 mL/min?
edoxaban
Oops!
Check
Okay!
Check
10
×
How are argatroban and bivalirudin monitored in HIT?
aPTT
Oops!
Check
Okay!
Check
5
×
What are the two classifications of venous thromboembolism?
DVT and PE
Oops!
Check
Okay!
Check
5
×
What is the scoring tool in stroke prevention in afib to assess risk of major bleeding for patients on anticoagulation/
HAS-BLED
Oops!
Check
Okay!
Check
5
×
What criteria screening tool is used for DVT and PE?
Wells'
Oops!
Check
Okay!
Check
15
×
In afib, what are the 3 criteria for dose reduction for apixaban?
age 80 or greater, weight 60 kg or less, or SCr 1.5 mg/dL or greater
Oops!
Check
Okay!
Check
20
×
What population would a lower starting dose of warfarin be warranted?
frail, elderly, malnourished, liver/kidney disease, heart failure, or acute illness
Oops!
Check
Okay!
Check
×
boom
Lose 50 points!
Oops!
×
rocket
Go to first place!
Okay!
×
gift
Win 20 points!
Okay!
×
baam
Lose 25 points!
Oops!
25
×
All DOACs are a substrate of ______
P-glycoprotein
Oops!
Check
Okay!
Check
×
monster
Reset all scores!
Oops!
×
gift
Win 20 points!
Okay!
×
fairy
Take points!
5
10
15
20
25
×
baam
Lose 20 points!
Oops!
10
×
What population would a higher initial dosing of warfarin be warranted?
young and healthy
Oops!
Check
Okay!
Check
25
×
In stroke prevention in afib, when would warfarin be indicated over a DOAC?
valvular afib (defined as moderate to severe mitral stenosis or mechanical heart valve)
Oops!
Check
Okay!
Check
20
×
What are the 3 guidelines used for anticoagulation?
CHEST, NICE, ASH
Oops!
Check
Okay!
Check
15
×
Which DOAC is recommended if CrCl < 15 mL/min?
apixaban
Oops!
Check
Okay!
Check
15
×
What are the two types of HIT? Which one is clinically important?
Type I and II; Important: Type II
Oops!
Check
Okay!
Check
×
seesaw
Swap points!
Oops!
×
seesaw
Swap points!
Okay!
×
gift
Win 10 points!
Okay!
×
lifesaver
Give 20 points!
Oops!
×
Restart
Review
Join for Free
;
Your experience on this site will be improved by allowing cookies.
Allow cookies
